^
Association details:
| Biomarker: | FOLR1 expression |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Elahere (mirvetuximab soravtansine-gynx) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
863P - A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRa -positive solid tumours: Results in the endometrial cancer (EC) cohort
Published date:
09/14/2020
Excerpt:
Here we report the results in the EC cohort treated at the RP2D. 2 of the 4 evaluable EC pts at the RP2D achieved a partial response (PR). 1 PR was observed on cycle 7 (the only medium FRα level pt) and the second PR was on cycle 3. One pt. had SD after 4 cycles and remains on treatment, and 1 pt progressed in the 1st cycle. The combination of MIRV with G has promising clinical activity in FRα-positive EC.
Trial ID:
